company background image
PRTA logo

Prothena NasdaqGS:PRTA Stock Report

Last Price

US$28.53

Market Cap

US$1.5b

7D

4.8%

1Y

-47.2%

Updated

03 Mar, 2024

Data

Company Financials +

Prothena Corporation plc

NasdaqGS:PRTA Stock Report

Market Cap: US$1.5b

PRTA Stock Overview

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.

PRTA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Prothena Corporation plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prothena
Historical stock prices
Current Share PriceUS$28.53
52 Week HighUS$79.65
52 Week LowUS$24.29
Beta0.25
1 Month Change10.71%
3 Month Change-19.11%
1 Year Change-47.20%
3 Year Change33.50%
5 Year Change122.89%
Change since IPO296.25%

Recent News & Updates

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23

Recent updates

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23

Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Feb 08
Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Dec 20
Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Nov 24
Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Oct 27
Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Aug 25
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

May 10
What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Apr 23
We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

Mar 01
Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate

Dec 28
We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate

Prothena: Paying A Premium To Cover All The Alzheimer's Bases

Sep 29

Prothena GAAP EPS of -$0.88 misses by $0.31

Aug 08

Bearish: Analysts Just Cut Their Prothena Corporation plc (NASDAQ:PRTA) Revenue and EPS estimates

May 08
Bearish: Analysts Just Cut Their Prothena Corporation plc (NASDAQ:PRTA) Revenue and EPS estimates

Are Prothena Corporation plc (NASDAQ:PRTA) Investors Paying Above The Intrinsic Value?

Jan 10
Are Prothena Corporation plc (NASDAQ:PRTA) Investors Paying Above The Intrinsic Value?

Prothena: A Biotech Company With A Promising Pipeline

Dec 01

Shareholder Returns

PRTAUS BiotechsUS Market
7D4.8%2.3%1.2%
1Y-47.2%10.3%24.4%

Return vs Industry: PRTA underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: PRTA underperformed the US Market which returned 24.4% over the past year.

Price Volatility

Is PRTA's price volatile compared to industry and market?
PRTA volatility
PRTA Average Weekly Movement11.3%
Biotechs Industry Average Movement12.0%
Market Average Movement6.1%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: PRTA's share price has been volatile over the past 3 months.

Volatility Over Time: PRTA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2012173Gene Kinneyhttps://www.prothena.com

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis.

Prothena Corporation plc Fundamentals Summary

How do Prothena's earnings and revenue compare to its market cap?
PRTA fundamental statistics
Market capUS$1.53b
Earnings (TTM)-US$147.03m
Revenue (TTM)US$91.37m

16.8x

P/S Ratio

-10.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRTA income statement (TTM)
RevenueUS$91.37m
Cost of RevenueUS$220.57m
Gross Profit-US$129.20m
Other ExpensesUS$17.83m
Earnings-US$147.03m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.74
Gross Margin-141.40%
Net Profit Margin-160.92%
Debt/Equity Ratio0%

How did PRTA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.